Intravenous Infusion of Fentanyl Has No Effect on Blood Concentration of Tacrolimus in Patients Receiving Hematopoietic Stem-Cell Transplantation
Conclusions: Intravenous infusion of fentanyl does not affect the pharmacokinetics of TAC.
Chronic wounds impact more than 6.5 million patients in the United States with a cost of treatment of approximately $65 billion each year. Traditional methods of repair for pressure ulcers include skin flaps which result in high morbidity and prolonged length of stay or skin grafts which may require large areas for harvesting and often fail. We evaluated the use of epidermal stem cell grafting in pressure ulcers.
Reconstruction of bone defects represents a major challenge due to its poor self-regenerating capabilities. Mesenchymal stem cells (MSC) have been shown to have pro-osteogenic effects in vitro and in vivo. Recently, there has been a paradigm shift implying the MSC-derived secretome to be the key player in tissue engineering, rather than the differentiation potential of MSCs. MSC-derived microvesicles (MV) have been shown to enhance osteogenic function in vitro and in vivo via transfer of osteogenic miRNAs and proteins.
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation; CMV Infection Intervention: Biological: CMV-TCR-T cells Sponsor: Xiao-Jun Huang Recruiting
Conditions: Allogeneic Stem Cell Transplantation; SARS-CoV2 Infection Intervention: Sponsor: Central Hospital, Nancy, France Completed
In utero fetal therapy offers the opportunity to prevent and treat diseases with a cellular or genetic basis. Components of successful fetal treatment include isolation of a replacement cell population, in utero stem cell transplantation, cell engraftment with fetal immune tolerance, and ongoing cell function. Fetal gene therapy with CRISPR-Cas9 represents an exciting potential therapy for genetic diseases not amenable to gene supplementation via adenoviral vector transduction. These fetal therapies have unique ethical and safety considerations. Clinical trials for in utero cell therapy are underway, as additional discover...
The aim of this study was to provide a brief overview on the background and rationale on treating fetuses and children suffering from osteogenesis imperfecta (OI) with mesenchymal stem cells (MSCs). MSCs ability to migrate, engraft, and differentiate into bone cells and to act via paracrine effects on the recipient’s tissues makes these cells promising candidates as a clinical therapy for OI. Animal work and limited clinical studies in humans support the use of MSC in treating OI. Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and thereby ...
Autologous hematopoietic stem cell transplantation for the treatment of active secondary progressive MS is associated with better disability outcomes than other immunotherapies, a new Italian study suggests.Medscape Medical News
Condition: Autologous Haematopoietic Stem Cell Transplant Intervention: Drug: plerixafor + G-CSF Sponsor: Sanofi Not yet recruiting
Hematopoietic stem cells (HSCs) are the only cells within the hematopoietic system that possess the combined ability to differentiate into all lineages of functional blood cells and self-renew indefinitely to sustain hematopoiesis throughout life. HSCs were originally hypothesized to exist after the discovery that transplantation of healthy bone marrow (BM) cells could rescue irradiated recipient animals and replenish their hematopoietic cells through a tremendously dynamic process. The hypothesis for the existence of HSCs was reinforced when cells with multilineage capacity were discovered in 1961 by Drs.
AbstractThe CD123-directed cytotoxin tagraxofusp (ELZONRIS®) is the first treatment approved in the EU for first-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults. BPDCN is a rare disease that affects mainly older patients and is usually treated with acute leukaemia-type multi-drug chemotherapy regimens followed, if possible, by stem cell transplantation (SCT). In the largest prospective trial conducted in BPDCN to date, treatment with tagraxofusp led to high rates of early and durable response in patients with previously untreated BPDCN, and enabled bridging to SCT in half of those who r...